OTHER GROUP COMPANIES
market

Zydus Cadila receives USFDA approval for Pimavanserin Capsules

Zydus Cadila receives USFDA approval for Pimavanserin Capsules

December 31, 2021 3:40 IST | capital market
Zydus Cadilas U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the USFDA to market Pimavanserin Capsules in the strength of 34 mg (USRLD: Nuplazid? Capsules).

Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis.

The drug will be manufactured at the groups formulation manufacturing facility at SEZ Ahmedabad. The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Powered by Capital Market - Live News

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity